Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: GDC-0941; Pictilisib; RG-7321

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PIramed; The Institute of Cancer Research
  • Developer Brighton & Sussex University Hospitals NHS Trust; Genentech; Roche
  • Class Antineoplastics; Pyrimidines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Apr 2016 Genentech completes a phase II trial in Breast cancer (Combination therapy, Second-line therapy or greater) in USA, Argentina, Australia, Belgium, Canada, Chile, Czech Republic, Denmark, France, Germany, Hong Kong, Israel, Italy, South Korea, Malaysia, Mexico, New Zealand, Peru, Russia, Singapore, Spain, Thailand and the UK (NCT01437566)
  • 01 Apr 2016 Genentech completes a phase II trial in Non-small cell lung cancer (Combination therapy, First-line therapy, Metastatic disease) in USA, Australia, Spain, Russia, Israel, Hungary, Argentina, Netherlands, United Kingdom, Ukraine, Italy, Germany, France, Chile, Canada, Brazil (PO) (NCT01493843)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top